	2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
	2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31	TTM Jun 30
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M IR
Total Revenue	48.26	65.10	69.05	90.04	100.89	123.11	135.94	178.07	183.27	214.33	235.01	266.09	304.55	311.10	332.60	325.74
Cost of Operating Revenue	17.17	26.54	25.20	41.64	39.76	49.16	50.86	62.72	59.71	73.69	92.98	116.26	139.38	129.84	120.37	98.32
Gross Profit	31.09	38.56	43.85	48.40	61.13	73.95	85.08	115.34	123.56	140.64	142.03	149.83	165.17	181.26	212.23	227.42
Gross Margin	64.4	59.2	63.5	53.8	60.6	60.1	62.6	64.8	67.4	65.6	60.4	56.3	54.2	58.3	63.8	69.8
Total Operating Expenses	33.81	47.47	49.68	70.39	72.98	89.00	98.33	121.64	140.57	158.99	191.60	236.18	268.06	266.37	264.62	260.86
Operating Profit	14.45	17.63	19.37	19.65	27.91	34.11	37.60	56.42	42.70	55.34	43.40	29.91	36.48	44.74	67.98	64.88
Operating Margin	29.9	27.1	28.0	21.8	27.7	27.7	27.7	31.7	23.3	25.8	18.5	11.2	12.0	14.4	20.4	19.9
Financing Income/(Expense) - Net	-2.63	-3.29	-6.60	-4.33	-3.55	-3.33	-3.81	-5.65	-6.36	-5.31	-2.09	-6.30	-16.99	-10.15	-1.59	76.08
Profit before Taxes	11.90	14.41	13.37	18.20	24.81	30.93	36.12	56.86	41.33	50.10	53.50	40.15	31.95	39.57	75.84	157.33
Income Taxes	4.41	5.34	4.20	4.82	5.63	8.15	13.05	16.16	10.32	15.41	14.02	12.12	10.79	10.75	18.35	20.41
Profit after Tax	7.61	9.26	9.45	13.60	19.20	23.55	25.62	41.57	29.17	34.43	39.32	26.63	18.89	27.49	55.64	136.18
PAT Margin	15.8	14.2	13.7	15.1	19.0	19.1	18.8	23.3	15.9	16.1	16.7	10.0	6.2	8.8	16.7	41.8
EPS - Basic - ex Extraordinary Items	13.42	12.85	11.11	15.98	22.57	27.68	30.12	48.86	34.29	40.47	46.22	31.30	22.20	32.31	65.40	158.68
EPS - Diluted - ex Extraordinary Items	13.42	12.85	11.11	15.98	22.57	27.68	30.12	48.86	34.29	40.47	46.22	31.30	22.20	32.31	65.40	158.68
EBIT	14.45	17.63	19.37	19.65	27.91	34.11	37.60	56.42	42.70	55.34	43.40	29.91	36.48	44.74	67.98	64.88
EBITDA	18.57	22.06	24.78	25.17	33.66	41.23	47.39	68.18	55.93	68.66	59.98	50.61	53.65	61.54	86.86	86.62
EBITDA Margin	38.5	33.9	35.9	28.0	33.4	33.5	34.9	38.3	30.5	32.0	25.5	19.0	17.6	19.8	26.1	26.6

Balance Sheet

Abridged

Understanding Balance Sheet

Hester Biosciences Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	C 2013 Mar 31	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	C 2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	C 2013 Mar 31	2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	2018 Mar 31	C 2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Source:	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR
Total Current Assets	46.12	49.80	57.10	60.00	74.17	79.97	98.45	141.66	159.31	161.51	194.76	227.59	214.62	195.17	208.56
Long-Term Investments	-	0.28	0.28	-	0.07	-	-	-	0.00	0.00	21.24	25.30	29.93	34.05	42.58
Property Plant & Equipment - Net	45.61	66.54	74.28	91.91	100.42	123.21	141.38	151.39	216.29	241.33	317.04	405.04	407.58	409.35	411.06
Total Non-Current Assets	49.30	73.90	85.12	100.45	105.85	132.91	145.59	157.80	227.29	249.54	367.40	442.37	447.73	458.21	469.38
Total Assets	95.43	123.70	142.22	160.45	180.01	212.88	244.04	299.45	386.60	411.05	562.16	669.97	662.35	653.38	677.94
Total Current Liabilities	28.22	38.89	45.47	35.01	37.07	38.01	54.63	48.66	83.47	61.37	96.90	148.70	105.78	125.18	152.48
Long Term Debt	1.29	13.71	15.52	31.79	33.09	44.62	36.54	58.35	76.48	82.84	169.81	190.48	187.11	138.84	96.28
Total Non-Current Liabilities	6.15	16.31	20.46	37.66	35.46	48.32	44.41	69.06	90.65	95.60	178.16	200.47	200.02	148.32	108.44
Total Liabilities	34.37	55.20	65.93	72.66	72.53	86.33	99.04	117.72	174.12	156.97	275.06	349.17	305.81	273.51	260.92
Total Shareholders' Equity	59.76	67.30	75.01	84.92	102.83	121.95	140.63	178.03	207.06	246.43	279.69	311.98	345.46	367.48	409.47
Minority Interest	1.30	1.20	1.28	2.87	4.65	4.60	4.37	3.70	5.42	7.65	7.41	8.82	11.08	12.40	7.55
Total Equity	61.06	68.49	76.29	87.79	107.48	126.55	145.00	181.73	212.49	254.08	287.10	320.79	356.54	379.88	417.02
Total Liabilities & Equity	95.43	123.70	142.22	160.45	180.01	212.88	244.04	299.45	386.60	411.05	562.16	669.97	662.35	653.38	677.94

Cash Flow

Abridged

Understanding Cash Flow Statement

Hester Biosciences Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	R 2012 Mar 31	2013 Mar 31	R 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	R 2012 Mar 31	2013 Mar 31	R 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	R 2017 Mar 31	C 2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Period length: Source:	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR
Operating CF bef Changes in Working Cap	15.23	13.48	9.39	15.69	24.61	31.26	36.38	52.48	44.65	56.07	45.22	32.35	31.46	42.27	90.68
Working Capital - Increase/(Decrease)	-3.76	-5.04	-6.25	-0.33	-9.37	0.11	-2.31	-12.26	-13.65	-0.78	-38.68	-20.84	3.63	9.95	-31.14
Net CF from Operating Activities	11.47	8.43	3.15	15.36	15.24	31.37	34.07	40.23	31.00	55.30	6.53	11.51	35.09	52.21	59.53
Capital Expenditures - Net	10.56	25.35	13.11	18.59	13.52	30.10	22.97	22.54	72.52	40.70	95.53	77.74	24.34	20.32	17.44
Net CF from Investing Activities	-10.36	-22.72	-14.80	-21.35	-13.41	-30.26	-25.91	-21.88	-74.85	-39.64	-116.85	-77.51	-24.55	-19.83	-4.90
Dividends Paid - Cash - Total	1.82	0.57	1.70	1.70	5.19	4.20	6.45	10.26	7.18	5.62	8.51	8.51	6.80	5.17	6.03
Stock - Issuance/(Retirement) - Net	4.93	-	-	4.89	1.41	0.73	-	-	-	1.96	-0.40	-	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	-5.02	16.15	15.46	8.65	2.27	8.80	-0.59	18.97	28.05	-22.90	116.87	38.86	-30.30	-33.42	-36.13
Net Cash Flow from Financing Activities	0.99	13.16	13.84	11.29	-2.97	5.33	-7.04	9.29	26.29	-14.19	114.15	54.35	-11.10	-38.59	-42.15
Free Cash Flow to Equity	-4.11	-0.76	5.49	5.42	3.99	10.07	10.51	36.65	-13.47	-8.30	27.87	-27.37	-19.55	-1.53	5.96
Free Operating CF net dividend	-1.07	-17.49	-11.69	-5.73	-3.84	-3.07	4.65	7.32	-49.68	8.94	-97.68	-74.75	3.89	26.45	35.68
Free Operating CF	0.75	-16.92	-9.99	-4.02	1.34	1.13	11.10	17.57	-42.50	14.55	-89.18	-66.25	10.69	31.62	41.70

Business Segment Analysis

FY End:

Mar 26

Hester Biosciences Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Animal Healthcare (70.1%)₹ 1.87 CrPoultry Healthcare (29.9%)₹ 0.80 CrOthers (0.0%)₹ 0.00 Cr

Revenue / Sales

Poultry Healthcare (61.9%)₹ 205.97 CrAnimal Healthcare (38.1%)₹ 126.63 Cr

Assets

Unallocated (48.6%)₹ 329.20 CrAnimal Healthcare (33.2%)₹ 225.39 CrPoultry Healthcare (18.2%)₹ 123.36 Cr

Regional Segment Analysis

FY End:

Mar 26

Hester Biosciences Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

In India (78.8%)₹ 261.97 CrOutside India (21.2%)₹ 70.63 Cr

Historical Segment Analysis

Track how Hester Biosciences Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Business

Regional

Business

	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31
Animal Healthcare	0	0	0	0	0	14	1	0	67	1	0	11	1	3	2
Poultry Healthcare	8	20	25	9	7	16	20	12	0	40	22	60	15	15	1
Unallocated	3	5	3	11	8	0	1	0	-	-	-	0	0	-	-
Petcare	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-
Others	-	-	-	-	-	-	-	-	-	-	-	-	-	6	0

Frequently Asked Questions

What is the revenue of Hester Biosciences Ltd.?

The latest trailing twelve month revenue of Hester Biosciences Ltd. is ₹ 325.74 Cr, reflecting a 1-year growth of 4.09% and a 3-year CAGR of 2.41%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Hester Biosciences Ltd.?

The latest trailing twelve month net profit (PAT) of Hester Biosciences Ltd. is ₹ 135.93 Cr, with a 3-year earnings CAGR of 65.32%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Hester Biosciences Ltd.?

The trailing twelve month EBITDA of Hester Biosciences Ltd. is approximately ₹ 66.58 Cr (based on an operating margin of 20.44%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Hester Biosciences Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Hester Biosciences Ltd. is 158.68. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Hester Biosciences Ltd.?

The debt-to-equity ratio of Hester Biosciences Ltd. stands at 0.48. The interest coverage ratio is 5.32x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Hester Biosciences Ltd.?

The estimated book value per share of Hester Biosciences Ltd. is 481.33 (derived from a P/B ratio of 4.88 and market price of ₹ 2,347.20), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Hester Biosciences Ltd.?

The trailing twelve month operating cash flow of Hester Biosciences Ltd. is ₹ 59.53 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Hester Biosciences Ltd. report consolidated or standalone financials?

Hester Biosciences Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.